Skip to main content

Barton Shane's Form 4 filing

BioAge Labs, Inc. (BIOA) · filed Jul 1, 2026

Accession no.
0001836297-26-000005
Filed
Jul 1, 2026, 4:27 PM ET
Trade date
Jun 29-30, 2026
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 10 non-derivative transactions and 8 derivative transactions. Open-market sales total $1.58M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Barton ShaneCIK 0001836297Officer (Principal Accounting Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jun 29, 2026Common StockMOption exerciseAcquired+9,301$10.85+$100,915.8511,933Direct
Jun 29, 2026Common StockMOption exerciseAcquired+7,261$8.39+$60,919.7919,194Direct
Jun 29, 2026Common StockMOption exerciseAcquired+8,958$4.30+$38,519.428,152Direct
Jun 29, 2026Common StockMOption exerciseAcquired+14,198$4.38+$62,187.2442,350Direct
Jun 29, 2026Common StockSSaleDisposed−42,350$25.21F2−$1,067,575.740Direct
Jun 30, 2026Common StockMOption exerciseAcquired+4,290$10.85+$46,546.54,290Direct
Jun 30, 2026Common StockMOption exerciseAcquired+4,000$8.39+$33,5608,290Direct
Jun 30, 2026Common StockMOption exerciseAcquired+4,065$4.30+$17,479.512,355Direct
Jun 30, 2026Common StockMOption exerciseAcquired+7,861$4.38+$34,431.1820,216Direct
Jun 30, 2026Common StockSSaleDisposed−20,216$25.19F3−$509,176.350Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jun 29, 2026Common StockMOption exerciseDisposed−9,301$0.00$017,589Direct
Jun 29, 2026Common StockMOption exerciseDisposed−7,261$0.00$021,016Direct
Jun 29, 2026Common StockMOption exerciseDisposed−8,958$0.00$031,042Direct
Jun 29, 2026Common StockMOption exerciseDisposed−14,198$0.00$075,802Direct
Jun 30, 2026Common StockMOption exerciseDisposed−4,290$0.00$013,299Direct
Jun 30, 2026Common StockMOption exerciseDisposed−4,000$0.00$017,016Direct
Jun 30, 2026Common StockMOption exerciseDisposed−4,065$0.00$026,977Direct
Jun 30, 2026Common StockMOption exerciseDisposed−7,861$0.00$067,941Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.79 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.

Referenced by the price of 1 transaction in Table I.

F3

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.42 per share, inclusive.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)